Chromium picolinate and biotin combination reduces atherogenic index of plasma in patients with type 2 diabetes mellitus: A placebo-controlled, double-blinded, randomized clinical trial

American Journal of the Medical Sciences

Volumn 333, Issue 3, 2007, Pages 145-153

  Geohas, Jeff ^a   Daly, Anne ^b   Juturu, Vijaya ^c,d   Finch, Manley ^c   Komorowski, James R ^c  

^a Chicago Research Center   (United States)

^b Springfield Diabetes and Endocrine Center   (United States)

^c Nutrition 21 ^*  (United States)

^d Nutrition 21 Inc   (United States)

Author keywords

Atherogenic index; Biotin; Chromium; Diabetes; Dyslipidemia

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BIGUANIDE; BIOLOGICAL MARKER; BIOTIN PLUS CHROMIUM PICOLINATE; CHROMIUM; DIACHROME; FRUCTOSAMINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SULFONYLUREA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; AREA UNDER THE CURVE; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ADULT; BIOTIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHROMIUM; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PICOLINIC ACIDS; TRIGLYCERIDES;

EID: 34547524331     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318031b3c9     Document Type: Article

References (58)

1. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
2. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
3. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
4. Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998;21:69-75.
5. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
6. Rosengren A, Welin L, Tsipogianni A, et al. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. BMJ 1989;299:1127-31.
7. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-8.
8. Fontbonne A, Eschwege E, Cambien F, et al. Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989;32:300-4.
9. Fletcher B, Berra K, Ades P, et al. Council on Cardiovascular Nursing; Council on Arteriosclerosis, Thrombosis, and Vascular Biology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Nutrition, Physical Activity, and Metabolism; Council on Stroke; Preventive Cardiovascular Nurses Association. Managing abnormal blood lipids: a collaborative approach. Circulation 2005;112:3184-209.
10. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003;52:453-62.
11. Bersot T, Haffner S, Harris WS, et al. Hypertriglyceridemia: Management of atherogenic dyslipidemia. J Fam Pract 2006;55:S1-8.
12. Nosadini R, Manzato E, Solini A, et al. Peripheral, rather than hepatic, insulin resistance and atherogenic lipoprotein phenotype predict cardiovascular complications in NIDDM. Eur J Clin Invest 1994;24:258-66.
13. Sijbrands EJ, Westendorp RG, Hoffer MJ, et al. Effect of apolipoprotein E and insulin resistance on VLDL particles in combined hyperlipidemic patients. Atherosclerosis 1996;126:197-205.
14. Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem 2004;50:1184-8.
15. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
16. Ekmekcioglu C, Prohaska C, Pomazal K, et al. Concentrations of seven trace elements in different hematological matrices in patients with type 2 diabetes as compared to healthy controls. Biol Trace Elem Res 2001;79:205-19.
17. Davies S, McLaren Howard J, Hunnisett A, et al. Agerelated decreases in chromium levels in 51,665 hair, sweat, and serum samples from 40,872 patients-implications for the prevention of cardiovascular disease and type II diabetes mellitus. Metabolism 1997;46:469-73.
18. Rajpathak S, Rimm EB, Li T, et al. Lower toenail chromium in men with diabetes and cardiovascular disease compared with healthy men. Diabetes Care 2004;27:2211-6.
19. Guallar E, Jimenez FJ, van't Veer P, et al. EURAMIC-Heavy Metals and Myocardial Infraction Study Group. Low toenail chromium concentration and increased risk of nonfatal myocardial infarction. Am J Epidemiol 2005;162:157-64.
20. Cefalu WT, Hu F. Role of chromium in human health and in diabetes. Diabetes Care 2004;27:2741-51.
21. Juturu V, Gormley J. Nutrients modulating metabolic syndrome risk factors. Current food science and nutrition 2005;1:1-11.
22. Fernandez-Mejia C. The pharmacological effects of biotin. J Nutr Biochem 2005;16:424-7.
23. Juturu V, Ruelle A, Hudson MS, et al. Improved glycemic control after diabetes education and chromium picolinate/biotin supplementation in type 2 diabetes: results from patients experience pilot program. Trace Elem Electrolytes 2006;23:66-72.
24. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
25. McGarry JD. Banting lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2001;51:7-18.
26. Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FERHDL). Clin Biochem 2001;34:583-8.
27. Hu YM, Tian HM, Liu R, et al. [Atherogenic index of plasma is associated with carotid intima-media thickness in patients with type 2 diabetes mellitus] Sichuan Da Xue Xue Bao Yi Xue Ban 2004;35:696-707.
28. Grover SA, Levington C, Paquet S. Identifying adults at low risk for significant hyperlipidemia: a validated clinical index. J Clin Epidemiol 1999;52:49-55.
29. Gaziano JM, Hennekens CH, O'Donnell CJ, et al. Fasting triglycerides, high-density lipoprotein and the risk of myocardial infarction. Circulation 1997;96:2520-25.
30. Tan MH, Loh KC, Dobiasova M, et al. Fractional esterification rate of HDL particles in patients with type 2 diabetes: relation to coronary heart disease risk factors. Diabetes Care 1998;21:139-42.
31. Feingold KR, Grunfeld C, Pang M, et al. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetics. Arterioscler Thromb 1992;12:1496-502.
32. Ronnemaa T, Laakso M, Pyorala K, et al. High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and nondiabetic subjects. Arterioscler Thromb 1991;11:80-90.
33. Lehto S, Ronnemaa T, Pyorala K, et al. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type II diabetes. Diabetologia 2000;43:148-55.
34. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-8.
35. Dobiasova M. Atherogenic index of plasma [log(triglycerides/HDL- cholesterol)]: theoretical and practical implications. Clin Chem 2004;50:1113-5.
36. Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998;97:1029-36.
37. Talmud PJ, Hawe E, Miller GJ, et al. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002;22:1918-23.
38. Iso H, Naito Y, Sato S, et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 2001;153:490-9.
39. Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetic states: relationship to atherogenesis. Diabetes Care 1991;14:839-55.
40. The BIP Study Group: Secondary prevention by raising HDL-C and reducing triglycerides in patients with coronary artery disease. The Bezafibrate infarction Prevention (BIP) study. Circulation 2000;102:21-7.
41. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8.
42. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
43. Clearfield M, Downs JR, Lee M, et al. Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines. Am J Cardiol 2005;96:1674-80.
44. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992;70:733-7.
45. Huttunen JK, Manninen V, Manttari M, et al. The Helsinki Heart Study: central findings and clinical implications. Ann Med 1991;23:155-9.
46. Lemieux I, Lamarche B, Couillard C, et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med 2001;161:2685-92.
47. Mozaffari MS, Patel C, Ballas C, et al. Effects of chronic chromium picolinate treatment in uninephrectomized rat. Metabolism 2005;54:1243-9.
48. Anderson R. Stress Effects on Chromium Nutrition in Humans and Animals, 10th ed. Nottingham, England: University Press; 1994.
49. Mita Y, Ishihara K, Fukuchi Y, et al. Supplementation with chromium picolinate recovers renal Cr concentration and improves carbohydrate metabolism and renal function in type 2 diabetic mice. Biol Trace Elem Res 2005;105:229-48.
50. Kozlovsky AS, Moser PB, Reiser S, et al. Effects of diets high in simple sugars on urinary chromium losses. Metabolism 1986;35:515-8.
51. Lukaski HC, Bolonchuk WW, Siders WA, et al. Chromium supplementation and resistance training: effects on body composition, strength and trace element status of men. Am J Clin Nutr 1996;63:954-65.
52. Tan MH, Jones D, Willis B, et al. Atherogenic index of plasma in Bermudians with diabetes. Diabetes Res Clin Pract 2000;50(Suppl 1):S132.
53. Wu S, Xue Gong Yi. The change of atherogenic index of plasma (AIP) level in type 2 diabetic pedigrees acarbose or glimepiride in therapy of type 2 diabetes mellitus. Cheng Xue Za Zhi 2005;22:560-4.
54. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor to cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population based prospective studies. J Cardiovasc Risk 1996;3:213-9.
55. 1 and dense LDL in type 2 diabetes. Arterioscler Thromb Vasc Biol 2001;21:282-9.
56. Murakami T, Michelagnoli S, Longhi R, et al. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol 1995;15:1819-28.
57. Dobiá1ová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apo B-lipoprotein-depleted plasma (FERHDL). Clin Biochem 2001;34:583-8.
58. Ravina AL, Slezak A, Rubal N, et al. Clinical use of the trace element chromium (III) in the treatment of diabetes mellitus. J Trace Elements Med Biol 1995;8:183-90.